Sharemaestro Newsreel

GH Research PLC (GHRS) grants 102,202 share options to director Michael Forer

GH Research PLC (GHRS) director Michael Forer received two grants of share options totaling 102,202 Ordinary Shares, both with an exercise price of $0.0250 per share and expiring on August 11, 2033. One grant of 2,202 options is immediately vested but not exercisable until …

ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY

The Rosen Law Firm announces a class action lawsuit on behalf of purchasers of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) securities between March 9, 2026, and June 24, 2026. Investors who bought shares during this period are encouraged to secure counsel before the October 5, …

RYTM (RYTM) insider plans Form 144 sale of option and RSU shares

An insider at Rhythm Pharmaceuticals (RYTM) has filed a Form 144 indicating a proposed sale of 75,834 common shares through Morgan Stanley Smith Barney LLC. This total includes 56,601 shares from stock option exercises dated August 13, 2026, and 19,233 shares from Restricted Stock …

Elicio Therapeutics (ELTX) faces going-concern risk after $20M loss and trial miss

Elicio Therapeutics reported a net loss of $20.0 million for the first half of 2026 and faces substantial doubt about its ability to continue as a going concern, with existing cash expected to fund operations only into Q1 2027. The company's lead Phase 2 …

Tempest Therapeutics (TPST) expands CAR-T pipeline amid $32.9M loss and cash strain

Tempest Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Form 8K Mink Therapeutics Inc For: 13 August By Investing.com

This article reports that Mink Therapeutics Inc. filed a Form 8K on August 13. The company's stock symbol INKT is mentioned, showing a slight increase of 2.45%. No further details about the content of the Form 8K are provided.

Ensysce Biosciences (ENSC) widens loss as cash falls, adds funding via Cy Biopharma deal

Kyntra Bio: Q2 Earnings Snapshot

ARS PHARMACEUTICALS ($SPRY) Releases Q2 2026 Earnings

This article first appeared on GuruFocus. Total Revenue: $33.7 million in Q2 2026, reflecting a combination of net product, collaboration, and supply revenue. US Net Product Revenue: $26.2 million for the second quarter. Total Operating Expenses: $95.1 million in Q2 2026, including $12.8 million …

Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors

Tempest Therapeutics announced a collaboration with Senlang Biotechnology to advance its TPST-4003 in vivo CAR-T product candidates, targeting first patient dosing in late 2026 and initial clinical data in early 2027. The company also appointed Drake Richey and Dr. John Yee to its Board …

NEKTAR THERAPEUTICS ($NKTR) Releases Q2 2026 Earnings

Edesa Reports $5.4 Million Q3 Loss as EB06 Phase 2 Site Activation Begins

Edesa Biotech (EDSA) reported a net loss of $5.4 million for Q3 2026, an increase from $1.7 million in the prior year, primarily due to rising operating expenses from its Phase 2 EB06 vitiligo study. The company is beginning site activation for this study …

Elicio Therapeutics: Q2 Earnings Snapshot

Cingulate (NASDAQ:CING) Posts Quarterly Earnings Results

Candel Therapeutics (NASDAQ:CADL) Releases Earnings Results, Misses Expectations By $0.30 EPS

* Candel Therapeutics press release [https://seekingalpha.com/pr/20618191-candel-therapeutics-reports-second-quarter-2026-financial-results-and-recent-corporate] (CADL [https://seekingalpha.com/symbol/CADL]): Q2 GAAP EPS of -$0.52 misses by $0.29. * Cash and cash equivalents of $201.6 million, as of June 30, 2026, are expected to be sufficient to fund the Company’s current operating plan into Q1 2028, …

Alpha Cognition reports Q2 revenue growth, narrows loss By Investing.com

Alumis Inc. (ALMS) reports $235M loss but ends quarter with $502M cash

Rani Therapeutics (RANI) boosts liquidity with $20M raise and Chugai revenue

Assembly Biosciences (ASMB) boosts cash to $320M and narrows loss

Moleculin Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Polaryx Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Cibus (CBUS) narrows Q2 2026 loss as cash burn falls and regulatory tailwinds build

Nektar Therapeutics Announces Second Quarter 2026 Financial Results

Celcuity GAAP EPS of -$1.44 misses by $0.28

* Celcuity press release [https://seekingalpha.com/pr/20619145-celcuity-inc-reports-release-of-second-quarter-2026-financial-results-and-provides-corporate] (CELC [https://seekingalpha.com/symbol/CELC]): Q2 GAAP EPS of -$1.44 misses by $0.28. * Total operating expenses were $66.1 million for the second quarter of 2026, compared to $44.0 million for the prior year period. Research and development (“R&D”) expenses were $31.1 …

Assembly Biosciences: Q2 Earnings Snapshot

Price to book forward of Humacyte, Inc. – NASDAQ:HUMAW

This article focuses on the "Price to book forward" financial metric for Humacyte, Inc., traded on NASDAQ under the symbol HUMAW. It provides a snapshot of this financial data point within the context of the company's financial overview on a trading platform. The content …

ALPHA COGNITION ($ACOG) Releases Q2 2026 Earnings, Stock Rises

ALPHA COGNITION ($ACOG) announced its Q2 2026 earnings, reporting -$0.40 per share, which met analyst estimates, and revenue of $6,090,000, exceeding expectations. Following the announcement, the stock price rose by 8.7%. The article also details recent insider trading activity, with significant purchases, and outlines …

MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

MapLight Therapeutics has reported its financial results for Q2 2026, highlighting positive outcomes from its Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia, which is now advancing to Phase 3. The company is primarily focusing its resources on ML-007C-MA, with ongoing enrollment for the …

Vivani Medical (VANI) widens GLP‑1 pipeline, funds runway into Q2 2027

Vivani Medical (VANI) has reported a net loss of $6.4 million for Q2 2026 and $13.2 million for the first half of 2026, with cash and equivalents totaling $19.9 million, which is projected to fund operations into Q2 2027. The company is advancing its …

Form 8K Vivani Medical Inc For: 13 August By Investing.com

This article reports on the filing of a Form 8K by Vivani Medical Inc. on August 13th, as tracked by Investing.com. The brief mention indicates a financial disclosure event for the company, with the stock symbol VANI noted to have experienced a -2.19% change.

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

Vivani Medical reported its second-quarter 2026 financial results, highlighting significant progress in its clinical development, including the successful dosing of all participants in its SLIM-1 Phase 1 trial for NPM-139, a semaglutide implant for chronic weight management. The company also announced a non-exclusive agreement …

20 Participants Dosed in Semaglutide Trial; Data Due in November

Vivani Medical (VANI) reported its Q2 2026 financial results, highlighting the successful dosing of all 20 participants in its Phase 1 SLIM-1™ trial for NPM-139, a semaglutide implant, with top-line data expected in November 2026. The company also announced a non-exclusive agreement with Novo …

Deerfield group discloses 2.88% Cogent Biosciences (COGT) position in amended 13G

A group of Deerfield entities and James E. Flynn have filed an amended Schedule 13G, revealing a collective beneficial ownership of 5,006,104 shares of Cogent Biosciences (COGT) common stock, which represents 2.88% of the outstanding class. The filing indicates shared voting and dispositive power …

Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Eikon Therapeutics reported its second-quarter 2026 financial results, highlighting significant clinical advancements across its oncology portfolio, particularly with abstracts accepted for the ESMO Congress 2026. The company detailed progress in clinical trials for its drug candidates EIK1001, EIK1003, EIK1004, and EIK1005, and announced key …

Kyntra Bio (Nasdaq: KYNB) turns Q2 profit as deconsolidation gain offsets cash burn